Veeva Announces AI Agent Platform and Standard Agent 'Falcon' for Autonomous Task Execution in Drug Development

Veeva Systems [NYSE: VEEV], a global pioneer in SaaS solutions for the life sciences industry (headquartered in Pleasanton, California, USA; Japan office in Shibuya, Tokyo; Japan General Manager: Hirotaka Chiba), announced on May 27, 2026, the launch of 'Veeva Falcon', an AI agent platform and standard agent designed to enable agentic labor (autonomous task execution by AI agents) for key drug development processes in life sciences.

Falcon integrates with the clinical, regulatory, and safety applications of the Veeva Development Cloud to help biopharmaceutical companies of all sizes reduce costs, increase speed, and maintain compliance. Falcon's initial focus areas are document ingestion and quality control for clinical master files, regulatory authority interactions, and case triage and intake for safety information management.

'Falcon is an important initiative for Veeva and represents our first offering in the agentic labor space,' said Peter Gassner, founder and CEO of Veeva Systems. 'We look forward to working with our customers through Falcon to help reduce costs and increase speed in drug development across the industry.'

Scheduled for early adopter availability in November 2026, Falcon is part of Veeva AI, Veeva's life sciences-specific AI solution.

[About Veeva Systems]

Veeva provides cloud services specifically for the life sciences industry through software, AI, data, and consulting. Committed to innovation, superior products, and customer success, Veeva serves over 1,500 companies, from the world's largest biopharmaceutical companies to emerging biotech firms. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit www.veeva.com.